No abstract available
Publication types
-
Clinical Trial, Phase I
-
Letter
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Drug Resistance, Neoplasm
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / pathology*
-
Oligopeptides / administration & dosage
-
Oligopeptides / adverse effects
-
Oligopeptides / therapeutic use*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology*
-
Proteasome Inhibitors / administration & dosage
-
Proteasome Inhibitors / adverse effects
-
Proteasome Inhibitors / therapeutic use*
-
Recurrence
-
Retreatment
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Oligopeptides
-
Proteasome Inhibitors
-
carfilzomib